ARDELYX, INC. Fair Value Adjustment of Warrants
ARDELYX, INC. (ARDX) reported Fair Value Adjustment of Warrants of $0 for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2017-02-17
- ARDELYX, INC. fair value adjustment of warrants for the quarter ending 2015-09-30 was $0.00.
- ARDELYX, INC. fair value adjustment of warrants for the quarter ending 2014-12-31 was $0.00.
- ARDELYX, INC. fair value adjustment of warrants for the quarter ending 2014-09-30 was $0.00.
- ARDELYX, INC. fair value adjustment of warrants for the quarter ending 2014-06-30 was -$1.01M.
- ARDELYX, INC. fair value adjustment of warrants for fiscal 2014 was $1.59M, a 54.56% decline from fiscal 2013.
- ARDELYX, INC. fair value adjustment of warrants for fiscal 2013 was $3.51M, a 269.05% increase from fiscal 2012.
- ARDELYX, INC. fair value adjustment of warrants for fiscal 2012 was $950.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $0.00 10-Q · filed 2015-11-12 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-12 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $0.00 derived: sum of 2 quarters · filed 2017-02-17 | -$1.01M derived: sum of 3 quarters · filed 2017-02-17 | $1.59M 10-K · filed 2017-02-17 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$1.01M derived: sum of 2 quarters · filed 2015-11-12 | $1.59M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$1.01M 10-Q · filed 2015-08-12 | $1.59M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | $2.60M 10-Q · filed 2015-05-12 | |||
| 2013-12-31 | $3.51M 10-K · filed 2016-03-04 | |||
| 2012-12-31 | $950.00K 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |